Rezafungin acetate is under clinical development by Napp Pharmaceuticals and currently in Phase III for Fungal Infections. According to GlobalData, Phase III drugs for Fungal Infections have a 51% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Rezafungin acetate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Rezafungin acetate overview

Rezafungin acetate (Rezzayo) is an antifungal agent. It is formulated as powder for solution for intravenous infusion route of administration. Rezzayo is indicated in patients 18 years of age or older who have limited or no alternative options for the treatment of candidemia and invasive candidiasis.

Rezafungin acetate is under development for the treatment and prophylaxis of aspergillosis in COVID-19 patients, pneumocystis pneumonia, Trichophyton mentagrophytes, Trichophyton rubrum, Microsporum gypseum, systemic candida infections including candidemia and related cases of invasive candidiasis, unspecified fungal infections. The drug candidate is a long acting echinocandin. It is administered intravaginally, subcutaneously and intravenously as a solution and a gel. The drug candidate was under development for the treatment of vulvovaginal candidiasis.

Napp Pharmaceuticals overview

Napp Pharmaceuticals, a subsidiary of Napp Pharmaceutical Holdings Ltd, is a developer and manufacturer of pharmaceutical products. The company offers prescription medicines for respiratory diseases, such as asthma; inflammatory conditions, such as ulcerative colitis, ankylosing spondylitis, rheumatoid arthritis, Crohn’s disease, and psoriasis; pain management; blood cancers and cardiovascular conditions. It works in partnership with National Health Service (NHS) and Bradford City Health Federation. Napp Pharmaceuticals is headquartered in Cambridge, the UK.

For a complete picture of Rezafungin acetate’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.